{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:41:25Z","timestamp":1790224885829,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12185-019-02618-w","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T03:01:41Z","timestamp":1550631701000},"page":"718-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis"],"prefix":"10.1007","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-8329","authenticated-orcid":false,"given":"Kosuke","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotaro","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Sonokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"2618_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O\u2019Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164\u201372.","journal-title":"N Engl J Med"},{"key":"2618_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079\u201382.","journal-title":"Science"},{"key":"2618_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"2618_CR4","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"2618_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"2618_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12185-017-2351-9","volume":"106","author":"N Usui","year":"2017","unstructured":"Usui N. Correction to: JSH guideline for tumors of hematopoietic and lymphoid tissues\u2014lukemia: 4. Chronic myelogenous leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2017;106:725\u20135.","journal-title":"Int J Hematol"},{"key":"2618_CR7","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347.","journal-title":"Arthritis Rheum"},{"key":"2618_CR8","first-page":"iii52","volume":"45","author":"C Sunderk\u00f6tter","year":"2006","unstructured":"Sunderk\u00f6tter C, Kuhn A, Hunzelmann N, Beissert S. Phototherapy. A promising treatment option for skin sclerosis in scleroderma? Rheumatology. 2006;45:iii52\u20134.","journal-title":"Rheumatology"},{"key":"2618_CR9","first-page":"1892","volume":"20","author":"PJ Clements","year":"1993","unstructured":"Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993;20:1892\u20136.","journal-title":"J Rheumatol"},{"key":"2618_CR10","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908\u201314.","journal-title":"J Clin Oncol"},{"key":"2618_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2010-08-302323","volume":"116","author":"CA Schiffer","year":"2010","unstructured":"Schiffer CA, Cortes JE, Saglio G, Le Coutre P, Guilhot F, Bahceci E, et al. Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib. Blood. 2010;116:358.","journal-title":"Blood"},{"key":"2618_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s12185-018-2517-0","volume":"108","author":"N Watanabe","year":"2018","unstructured":"Watanabe N, Takaku T, Takeda K, Shirane S, Toyota T, Koike M, et al. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper\/cytotoxic CD4 T cells in chronic myelogenous leukemia patients. Int J Hematol. 2018;108:588\u201397.","journal-title":"Int J Hematol"},{"key":"2618_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557\u201367.","journal-title":"J Clin Invest"},{"key":"2618_CR14","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1056\/NEJMoa052955","volume":"354","author":"S Svegliati Baroni","year":"2006","unstructured":"Svegliati Baroni S, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667\u201376.","journal-title":"N Engl J Med"},{"key":"2618_CR15","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1096\/fj.07-105627","volume":"22","author":"A Akhmetshina","year":"2008","unstructured":"Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22:2214\u201322.","journal-title":"FASEB J"},{"key":"2618_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/ard.2010.143974","volume":"70","author":"RF Spiera","year":"2011","unstructured":"Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70:1003\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2618_CR17","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1002\/art.30548","volume":"63","author":"D Khanna","year":"2011","unstructured":"Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one-year, phase I\/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540\u20136.","journal-title":"Arthritis Rheum"},{"key":"2618_CR18","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500\u20135.","journal-title":"Cancer Res"},{"key":"2618_CR19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1365-2133.2007.08093.x","volume":"157","author":"M Kido","year":"2007","unstructured":"Kido M, Takeuchi S, Hayashida S, Urabe K, Sawada R, Furue M. Assessment of abnormal blood flow and efficacy of treatment in patients with systemic sclerosis using a newly developed microwireless laser Doppler flowmeter and arm-raising test. Br J Dermatol. 2007;157:690\u20137.","journal-title":"Br J Dermatol"},{"key":"2618_CR20","doi-asserted-by":"crossref","unstructured":"Martyanov V, Kim G-HJ, Hayes W, Du S, Ganguly BJ, Sy O, et al. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS One 2017: e0187580.","DOI":"10.1371\/journal.pone.0187580"},{"key":"2618_CR21","doi-asserted-by":"publisher","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","volume":"3","author":"A Milano","year":"2008","unstructured":"Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008;3:e2696.","journal-title":"PLoS One"},{"key":"2618_CR22","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1182\/blood-2017-08-801019","volume":"130","author":"E Grockowiak","year":"2017","unstructured":"Grockowiak E, Laperrousaz B, Jeanpierre S, Voeltzel T, Guyot B, Gobert S, et al. Immature CML cells implement a BMP autocrine loop to escape TKI treatment. Blood. 2017;130:2860\u201371.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02618-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T19:22:27Z","timestamp":1582140147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02618-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2618"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02618-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"19 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}